The impending patent expiry of Stelara is prompting significant shifts in decision-making for both payers and providers. This anticipated "patent cliff" is driving strategic adjustments in anticipation of biosimilar competition.
When does Stelara’s main patent expire?
The primary U.S. patents for Stelara (ustekinumab) are set to expire in late 2023. However, additional patents covering its formulation and methods of use extend its market exclusivity potentially through 2030 [1]. This staggered expiry creates a complex landscape for future market entry.
How are payers preparing for Stelara’s patent expiry?
Payers are actively preparing for Stelara's patent cliff by developing strategies to manage the anticipated increase in treatment options and potential cost fluctuations. This includes evaluating and preparing for the formulary placement of biosimilar versions of Stelara once they become available [2]. Payers are also focusing on understanding the cost-effectiveness and clinical performance of biosimilars compared to the originator product to inform their reimbursement decisions.
What are providers considering regarding Stelara alternatives?
Healthcare providers are beginning to evaluate the landscape of potential Stelara biosimilars. Their considerations include the clinical interchangeability and therapeutic equivalence of these biosimilars, as well as the potential impact on patient care pathways and treatment regimens. Providers will need to assess the evidence supporting biosimilar efficacy and safety for conditions like plaque psoriasis and psoriatic arthritis [3].
What is the impact on Stelara pricing and market access?
The expiration of Stelara's patents is expected to lead to increased competition and downward pressure on pricing. As biosimilar versions enter the market, payers will likely negotiate more aggressively on price, potentially leading to significant cost savings compared to the current brand-name Stelara. This shift in pricing dynamics will influence market access for both the originator and biosimilar products.
Can biosimilars of Stelara enter before patent expiry?
The entry of Stelara biosimilars before the expiration of all relevant patents is dependent on the outcome of patent litigation. Pharmaceutical companies often file for patent extensions or defend their patents through legal challenges to maintain market exclusivity for as long as possible. Any successful challenges to these secondary patents could allow biosimilars to enter the market earlier than anticipated [1].
Who makes Stelara and what are its main competitors?
Stelara is manufactured by Janssen, a subsidiary of Johnson & Johnson. Its primary competitors in the biologic therapy space for its approved indications include drugs like Taltz (ixekizumab), Cosentyx (secukinumab), and Humira (adalimumab) [4]. The introduction of Stelara biosimilars will add further competitive pressure to this market.
Where can I find more information on drug patents and exclusivity?
Detailed information on drug patents, exclusivity periods, and the landscape of biosimilar development can be found on DrugPatentWatch.com [1].
---
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.healio.com/news/hematology-oncology/20230717/payers-prepare-for-stelara-biosimilar-launch
[3] https://www.ajmc.com/view/providers-face-challenges-in-navigating-biosimilar-adoption-for-stelara-and-other-drugs
[4] https://www. Drugs.com/drug-class/interleukins.html